Small and emerging biotech companies need
three things to get started in early development: a molecule, funding
and speed. The Tufts Center for the Study of Drug Development (CSDD)
recently compared cycle times and development economics between multi-
and single-source CDMO models finding that if you plan for drug
substance and drug product early in development, you can reap the
benefits of approximately $45 million in net gains from time savings and
increased revenue.
Download the article,
Tufts Study Uncovers the Economic Advantage of Single-Source Drug
Development and Manufacturing, to explore the results of the study.
